Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (all articles)

Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.

13 Jul, 2021 | 09:48h | UTC

J&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT

See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times

 


Another RCT evaluating the efficacy and quality of life of antibiotic-only treatment of acute uncomplicated appendicitis.

13 Jul, 2021 | 09:33h | UTC

A Randomized Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic-only Treatment of Acute Uncomplicated Appendicitis: Results of the COMMA Trial – Annals of Surgery (link to abstract – $ for full-text)

Related: A Randomized trial comparing antibiotics with appendectomy for appendicitis AND Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin AND Observational study: 67.1% success rate with nonoperative management of children with uncomplicated appendicitis AND Randomized Trial: Quality of Life and Patient Satisfaction at 7-Year Follow-up of Antibiotic Therapy vs. Appendectomy for Uncomplicated Acute Appendicitis AND Meta-Analysis: Antibiotic Treatment vs. Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children AND Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis – Pediatric Surgery International

 

Commentary on Twitter

 


Podcast | An Antibiotics Primer.

13 Jul, 2021 | 09:35h | UTC

#284 An Antibiotics Primer, with @IDdocAdi – The Curbsiders

 


M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.

13 Jul, 2021 | 09:18h | UTC

Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)

 


Review: Infectious disease-associated encephalopathies.

13 Jul, 2021 | 09:30h | UTC

Infectious disease-associated encephalopathies – Critical Care

 

Commentary on Twitter

 


Top 10 pearls for the recognition, evaluation, and management of maternal sepsis.

13 Jul, 2021 | 09:25h | UTC

Top 10 Pearls for the Recognition, Evaluation, and Management of Maternal Sepsis – Obstetrics & Gynecology

 


RCT: Comparison of nebulized ketamine at three different dosing regimens for treating painful conditions in the emergency department.

13 Jul, 2021 | 09:22h | UTC

Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.

12 Jul, 2021 | 03:14h | UTC

Heparin for Moderately Ill Patients with Covid-19 – medRxiv

Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. AND [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19

 

Commentary on Twitter (thread – click for more)

 


RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19.

12 Jul, 2021 | 03:09h | UTC

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial – The Lancet Respiratory Medicine

Commentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine

Related: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. AND RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 AND RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 AND [Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial AND Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 AND Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

 

Commentary on Twitter

 


Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.

12 Jul, 2021 | 01:41h | UTC

Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report – Annals of the American Thoracic Society

 


RCT: Another study shows that non-antibiotic outpatient treatment in mild acute diverticulitis is safe.

12 Jul, 2021 | 01:29h | UTC

Efficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)

Related: State of the Art Review: Management of colonic diverticulitis AND Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis – Diseases of the Colon & Rectum AND Antibiotics Do Not Reduce Length of Hospital Stay for Uncomplicated Diverticulitis in a Pragmatic Double-Blind Randomized Trial – Clinical Gastroenterology and Hepatology AND Randomized Trial: Antibiotic Avoidance Associated with Similar Long-term Outcomes in Uncomplicated Diverticulitis

 

Commentary on Twitter

 


M-A: Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections.

9 Jul, 2021 | 09:57h | UTC

Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis – Infectious Diseases and Therapy

 

Commentary on Twitter

 


Assessment and management of cardiovascular disease in the intensive care unit.

9 Jul, 2021 | 09:54h | UTC

Assessment and management of cardiovascular disease in the intensive care unit – Heart

 


Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

8 Jul, 2021 | 09:17h | UTC

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia – New England Journal of Medicine

 

Commentary on Twitter

 


Review: Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS.

8 Jul, 2021 | 09:01h | UTC

Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS – Intensive Care Medicine

 

Commentary on Twitter

 


Predictors of death and new disability after critical illness: a multicenter prospective cohort study.

8 Jul, 2021 | 08:59h | UTC

Predictors of death and new disability after critical illness: a multicentre prospective cohort study – Intensive Care Medicine

 

Commentary on Twitter

 


Study Commentary: Febrile Neutropenia – Procalcitonin vs. MASCC Score.

8 Jul, 2021 | 08:57h | UTC

Febrile Neutropenia – Procalcitonin vs MASCC Score – Journal Feed

Original study: Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department – The Journal of Emergency Medicine

 


M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.

7 Jul, 2021 | 09:02h | UTC

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis – JAMA

Editorial: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? – JAMA

Commentaries: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients – King’s College London AND WHO advises 2 monoclonal antibodies for severe COVID – CIDRAP

 

Commentary on Twitter (thread – click for more)

 


A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19.

7 Jul, 2021 | 09:03h | UTC

A living WHO guideline on drugs for covid-19 – The BMJ

 

Commentary on Twitter

 


WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access – “These are the first drugs found to be effective against COVID-19 since corticosteroids were recommended by WHO in September 2020”.

7 Jul, 2021 | 09:00h | UTC

WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


SAEM Guidelines for reasonable and appropriate care in the emergency department (GRACE): Recurrent, low-risk chest pain in the emergency department.

7 Jul, 2021 | 08:48h | UTC

Guidelines for reasonable and appropriate care in the emergency department (GRACE): Recurrent, low-risk chest pain in the emergency department – Academic Emergency Medicine

News release: SAEM publishes GRACE guidelines for recurrent, low-risk chest pain care in the ED – Society for Academic Emergency Medicine

Invited commentaries: GRACE-recurrent low-risk chest pain: A user’s guide AND Navigating uncertainty with GRACE: Society for Academic Emergency Medicine’s guidelines for reasonable and appropriate care in the emergency department

 


M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

7 Jul, 2021 | 08:52h | UTC

Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research – Transfusion Medicine

 


RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

6 Jul, 2021 | 10:16h | UTC

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial – BMC Infectious Diseases

Commentary: Ivermectin: balance of evidence shows no significant benefit against Covid-19 – MSN News

Related: Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. AND Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”. AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 


Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians.

6 Jul, 2021 | 10:21h | UTC

Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians – Nature Medicine

 


Editorial | Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions.

6 Jul, 2021 | 10:14h | UTC

Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions – Intensive Care Medicine

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.